<DOC>
	<DOC>NCT01254526</DOC>
	<brief_summary>This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with taxane-based chemotherapy regimens utilized in patients with locally recurrent or metastatic breast cancer.</brief_summary>
	<brief_title>Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Locally recurrent or metastatic breast cancer, not amenable to resection with curative intent For Arm C: Overexpression of HER2 Eastern Cooperative Oncology Group Performance Status of 0 or 1 Adequate hematologic and organ function Evaluable or measurable disease per RECIST (Response Evaluable Criteria in Solid Tumors) Female patients of childbearing potential must use an acceptable method of contraception to prevent pregnancy and to continue its use for the duration of the study Prior anticancer therapy of more than two regimens of systemic cytotoxic chemotherapy for advanced or metastatic breast cancer Prior anticancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy) within a specified timeframe of the first dose of study treatment History of Type 1 or Type 2 diabetes requiring regular medication History of clinically significant cardiac or pulmonary dysfunction History of malabsorption syndrome or other condition that would interfere with enteral absorption Any condition requiring fulldose anticoagulants Leptomeningeal disease as a manifestation of cancer Active infection requiring IV antibiotics Active autoimmune disease that is not controlled by nonsteroidal antiinflammatory drugs, inhaled steroids, or the equivalent of &lt;= 10 mg/day of prednisone Known clinically significant history of liver disease, including active viral, alcoholic, or other hepatitis, or cirrhosis Known HIV infection Known untreated or active CNS metastases Pregnancy, lactation, or breastfeeding Major surgical procedure, open biopsy, or significant traumatic injury within a within a specified timeframe of the first dose of study treatment For Arm B: Uncontrolled hypertension, complication from hypertension, myocardial infarctions, unstable angina, vascular disease or stroke within a specified timeframe of the first dose of study treatment Evidence of bleeding diathesis or significant coagulopathy including hemoptysis within a specified timeframe of the first dose of study treatment History of abdominal conditions (e.g., fistula, perforation, obstruction) that would preclude use of bevacizumab Serious, nonhealing wound, active ulcer, or untreated bone fracture Proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>